Showing results (221-230 of 270) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2022
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID studyMaria V Dieci, Giuseppe Azzarello, Vittorina Zagonel, et al.
The Oncologist|March 9, 2019
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study)Giulia Pasello, Giovanni Vicario, Fable Zustovich, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
JCO Precision Oncology|September 10, 2025
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?Riziero Esposito Abate, Alessandro Morabito, Michele Milella, et al.
Diagnostics (Basel, Switzerland)|October 12, 2019
BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic LaboratoriesEttore Capoluongo, Nicla La Verde, Massimo Barberis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, et al.
Pageof 27